p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: A multivariate analysis
- 30 April 2005
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 97 (1), 46-52
- https://doi.org/10.1016/j.ygyno.2004.12.053
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Critical evaluation of p53 as a prognostic marker in ovarian cancerExpert Reviews in Molecular Medicine, 2004
- In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Science, 2004
- Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: A multivariate analysis of expression of p53, retinoblastoma, and related proteinsInternational Journal of Gynecologic Cancer, 2003
- Ovarian cancer: strategies for overcoming resistance to chemotherapyNature Reviews Cancer, 2003
- The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinomaInternational Journal of Gynecologic Cancer, 2002
- Can Serum CA-125 Levels Predict the Optimal Primary Cytoreduction in Patients with Advanced Ovarian Carcinoma?Gynecologic Oncology, 2002
- p53 Mutations and Expression in Ovarian CancersInternational Journal of Gynecological Pathology, 1999
- p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivityZeitschrift für Krebsforschung und Klinische Onkologie, 1997
- Quantification of p53 in Epithelial Ovarian CancerGynecologic Oncology, 1997
- TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomasThe Journal of Pathology, 1997